Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease MONROVIA, Calif.–(BUSINESS WIRE)–Jul 23, 2007 – A first-in-class protein therapeutic drug candidate has been shown to selectively inhibit its therapeutic target, according to
Xencor Data from Pre-clinical XmAb™ Antibody Studies Presented at American Society of Hematology Meeting Monrovia, Calif. – December 10, 2007 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today the presentation of results from pre-clinical studies evaluating two
Xencor Completes $6 Million Bridge Financing with Novo Nordisk and Existing Investors Monrovia, CA – July 11, 2006 – Xencor, a biotherapeutics company developing protein and antibody therapeutics, today announced that it raised $6 million in a bridge financing from new investor Novo Nordisk and
Xencor Completes $45 Million Financing with MedImmune Ventures, Novo Nordisk and HealthCare Ventures Monrovia, CA – October 19, 2006 – Xencor, a company developing protein and antibody therapeutics, today announced that it raised $45 million in a private financing led by MedImmune Ventures, Inc.,
Xencor Co-Founder, Stephen Mayo, Presents Protein Design Automation Results at AAAS Meeting (BW Healthwire)–January 25, 1999—Stephen Mayo Ph.D., Associate Professor of Biology, California Institute of Technology and co-founder of Xencor Inc., presented new results from Protein Design AutomationTM,
Xencor Closes $12.3 Million in Financing (BW Healthwire)–June 14, 1999—Xencor Inc. announced the closing of a second round of private equity financing for $12.3 million. This financing was led by Stafford Investments LLC of Chicago, Illinois and will be used to accelerate the research, development
MONROVIA, Calif. , July 31, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Yujiro S.
MONROVIA, Calif. , Dec. 19, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced the appointment of Richard Ranieri
MONROVIA, Calif. , June 8, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Raphael Clynes
MONROVIA, Calif. --(BUSINESS WIRE)--Sep. 9, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente , M.D., to its board of